Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Gita Thanarajasingam*, Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, Nicole Gormley, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Yok Lam Kwong, Richard F Little, Matthew J MatasarMaria-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Abhilasha Nair, Loretta Nastoupil, Kaye Robertson, Surbhi Sidana, Karin E Smedby, Pieter Sonneveld, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, John F Seymour, Thomas M Habermann

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and combination regimens have adverse event profiles distinct from conventional finite cytotoxic chemotherapies. In 2018, a Commission comprising patient advocates, clinicians, clinical investigators, regulators, biostatisticians, and pharmacists representing a broad range of academic and clinical cancer expertise examined issues of adverse event evaluation in the context of both newer and existing therapies for haematological cancers. The Commission proposed immediate actions and long-term solutions in the current processes in adverse event assessment, patient-reported outcomes in haematological malignancies, toxicities in cellular therapies, long-term toxicity and survivorship in haematological malignancies, issues in regulatory approval from an international perspective, and toxicity reporting in haematological malignancies and the real-world setting. In this follow-up report, the Commission describes progress that has been made in these areas since the initial report.

Original languageEnglish
JournalThe Lancet. Haematology
Issue number5
Pages (from-to)e374-e384
Publication statusPublished - May 2022

Bibliographical note

Copyright © 2022 Elsevier Ltd. All rights reserved.


  • Antineoplastic Agents
  • Hematologic Neoplasms/complications
  • Humans
  • Neoplasms


Dive into the research topics of 'Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies'. Together they form a unique fingerprint.

Cite this